CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II
Briefings in Bioinformatics · 22.11.2024 · 26 (1)
DOI: 10.1093/bib/bbae595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 17.12.2024. Verfasst von Yunjian Chang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of RNA Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, …. Hauptthemen laut MEDLINE: Histocompatibility Antigens Class I, Peptides, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Strategic Priority Research Program of the Chinese Academy of Sciences, National Key R&D Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Human leukocyte antigen class I (HLA-I) and class II (HLA-II) proteins play an essential role in epitope binding and presentation to initiate an immune response. Accurate prediction of peptide-HLA (pHLA) binding and presentation is critical for developing effective immunotherapies. However, current tools can predict antigens exclusively for pHLA-I or pHLA-II, but not both; have constraints on peptide length; and commonly show unsatisfactory predictive accuracy. Here, we developed a convolution and attention-based model, CapHLA, trained with eluted ligand and binding affinity mass spectrometry data, to predict peptide presentation probability (PB) and binding affinities (BA) for HLA-I and HLA-II. In comparison with 11 other methods, CapHLA consistently showed improved performance in predicting pHLA BA and PB, particularly in HLA-II and non-classical peptide length datasets. Using CapHLA PB and BA predictions in combination with antigen expression level (EP) from transcriptomic data, we developed a neoantigen quality model for predicting immunotherapy response. In analyses of clinical response among 276 cancer patients given immunotherapy and overall survival in 7228 cancer patients, our neoantigen quality model outperformed other genetics-based models in predicting response to checkpoint inhibitors and patient prognosis. This study provides a versatile neoantigen screening tool, illustrating the prognostic value of neoantigen quality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of RNA Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences…
ORCID-Profile: Yunjian Chang
Förderung
- Strategic Priority Research Program of the Chinese Academy of Sciences
- National Key R&D Program of China
- National Natural Science Foundation of China
Zitieren
APA
Chang, Y., & Wu, L. (2024). CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II. Briefings in Bioinformatics, 26(1). https://doi.org/10.1093/bib/bbae595
Vancouver
Chang Y, Wu L. CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II. Briefings in Bioinformatics. 2024;26(1). doi:10.1093/bib/bbae595
BibTeX
@article{Chang2024,
author = {Chang, Yunjian and Wu, Ligang},
title = {CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II},
journal = {Briefings in Bioinformatics},
year = {2024},
volume = {26},
number = {1},
doi = {10.1093/bib/bbae595}
}
EUVIMED